Singapore, July 13 -- South Korea-based Samsung Bioepis has entered into a license agreement with Proteina Co. to collaborate on a government-supported national R&D initiative aimed at developing AI-based antibody therapeutics.

Published by HT Digital Content Services with permission from BioSpectrum Asia....